Author(s)

Phillip Crane^1*, Voltaire Nadurata², M. Asrar Ul Haq^1,2

¹Department of Cardiology, The Northern Hospital, Epping, Australia.
²Department of Cardiology, Bendigo Health, Bendigo, Australia.

Background: Vaccines remain the only viable and safe option to control transmission and minimise disease sequelae during the COVID-19 pandemic. Whilst multiple vaccines are available, evidence has emerged regarding the association between the ChAdOx1 nCoV-19 vaccine, platelets and thrombosis, manifesting in thrombotic thrombocytopaenia. Case Summary: We report a case of recurrent coronary artery thrombosis on triple antithrombotic therapy, namely aspirin, clopidogrel, and continuous intravenous heparin, nine days after the ChAdOx1 nCoV-19 vaccine, in a 63-year-old female with no significant history of cardiovascular disease. Conclusion: This case may suggest that the association between platelets, SARS-CoV-2, the ChAdOx1 nCoV-19 vaccine, and coronary thrombosis may remain incompletely understood and warrants further study. Clinicians should remain on high alert if presented with similar circumstances.

ST-Elevation Myocardial Infarction, Stent Thrombosis, ChAdOx1 nCoV-19, AstraZeneca, COVID-19, SARS-CoV-2

Crane, P. , Nadurata, V. and Asrar Ul Haq, M. (2022) Recurrent Coronary Artery Thrombosis on Triple Anti-Thrombotic Therapy, Is There a Possible Association with ChAdOx1 nCoV-19 Vaccination?. Case Reports in Clinical Medicine, 11, 234-243. doi: 10.4236/crcm.2022.116035.